ENDOTOXIN TESTING ASSAY AND METHOD OF SAME
20210262924 · 2021-08-26
Inventors
Cpc classification
G01N21/31
PHYSICS
G01N33/54373
PHYSICS
G01N21/7743
PHYSICS
International classification
Abstract
A pyrogenicity test method and assay of endotoxins allows for rapid and ultrahigh sensitivity testing of parenteral pharmaceuticals or medical devices that contact blood or cerebrospinal fluid by employing a Limulus Amoebocyte Lysate (LAL) assay monitored with a photonic-crystal biosensor. The photonic-crystal biosensor is capable of determining the presence of endotoxins in a test sample by detecting shifts in the resonant condition of an open microcavity affected by the changes in the refractive index of the analyte solutions used.
Claims
1. An endotoxin assay system comprising means for measuring endotoxin from a cell wall component of Gram-negative bacteria in an analyte by monitoring changes in a refractive index of the analyte.
2. The endotoxin assay system of claim 1, wherein the means for measuring endotoxins comprise a photonic crystal biosensor.
3. The endotoxin assay system of claim 1, wherein the means for measuring endotoxins comprise a photonic crystal total internal reflection (PC-TIR) biosensor.
4. The endotoxin assay system of claim 1, wherein the means for measuring endotoxins comprise Limulus Amoebocyte Lysate (LAL) reagents.
5. The endotoxin assay system of claim 3, further comprising at least one analyte well associated with the PC-TIR biosensor.
6. The endotoxin assay system of claim 3, further comprising means for providing polarized light to the PC-TIR biosensor.
7. The endotoxin assay system of claim 5, further comprising a prism for transmitting light to the PC-TIR biosensor and passing the light from the PC-TIR biosensor to a spectrometer for receiving the transmitted light.
8. The endotoxin assay system of claim 1, wherein the detection sensitivity of the system is at least less than or equal to 0.0005 EU/ml of the endotoxin.
9. The endotoxin assay system of claim 1, wherein an onset time for changes in the refractive index is determined to quantify the endotoxin concentration in the analyte.
10. The endotoxin assay system of claim 6, further comprising: a light source having a polarizer optically coupled thereto; a beam splitter optically coupled to the polarizer; a prism optically coupled to at least one of a plurality of analyte wells associated with the PC-TIR biosensor; and a spectrometer optically coupled to the prism.
11. The endotoxin assay system of claim 10 wherein an optical fiber is used to optically couple the light source.
12. The endotoxin assay system of claim 3, wherein the PC-TIR biosensor further comprises a plurality of microchannels or wells on a surface thereof.
13. The endotoxin assay system of claim 12, further comprising: a laser light source providing a polarized laser light beam; a spatial filter configured to receive a polarized laser light beam and expand the polarized laser light beam; a plurality of mirrors configured to direct the expanded polarized laser light beam toward the PC-TIR biosensor.
14. The endotoxin assay system of claim 12, further comprising: a lens configured to focus the polarized laser light beam into a line crossing at least one of the plurality of microchannels or wells on the surface of the PC-TIR biosensor; and an imaging device capable of imaging the reflected laser light beam to create an image, the image having a plurality of sections corresponding to a resonant angle of the laser light beam.
15. An endotoxin assay method comprising the steps of providing an analyte sample suspected of containing an endotoxin from lipopolysaccharide cell wall component of Gram-negative bacteria in an analyte; adding the analyte sample to at least one sample well on a photonic crystal biosensor; adding LAL reagent to the analyte sample; exposing the analyte sample to a focused laser line across the photonic crystal biosensor; generating an output beam reflected from the photonic crystal biosensor; imaging the output beam; and monitoring changes in a refractive index of the analyte sample.
16. The endotoxin assay method of claim 15, further comprising the step of providing a photonic crystal biosensor having an open cavity and a total internal reflection.
17. The endotoxin assay method of claim 16, further comprising the step of collimating the laser light prior to the step of exposing the analyte sample to a focused laser line.
18. The endotoxin assay method of claim 15, further comprising the step of measuring statistically significant shifts in the resonant condition of the biosensor within approximately two minutes of starting the LAL assay.
19. The endotoxin assay method of claim 15, further comprising the step of measuring statistically significant shifts in the resonant condition of the biosensor within approximately ten minutes of starting the LAL assay.
20. The endotoxin assay method of claim 15, wherein the reagent selected comprises Factor C or recombinant Factor C.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] The patent or application contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee
[0017]
[0018]
[0019]
[0020]
[0021]
[0022]
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0023] For purposes of clarity, the following terms used in this patent application will have the following meanings:
[0024] The terminology used herein is for the purpose of describing example embodiments only and is not intended to be limiting. As used herein, the singular forms “a,” “an,” and “the” may be intended to include the plural forms as well, unless the context clearly indicates otherwise. The terms “comprises,” “comprising,” “including,” and “having,” are inclusive and therefore specify the presence of stated features, integers, steps, operations, elements and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. The method steps, processes, and operations described herein are not to be construed as necessarily requiring their performance in the order discussed or illustrated, unless specifically identified as an order of performance. It is also to be understood that additional or alternative steps may be employed.
[0025] When an element or layer is referred to as being “on,” “engaged,” “connected,” or “coupled” to or with another element, it may be directly on, engaged, connected or coupled to the other element or layer, or intervening elements or layers may be present. In contrast, when an element is referred to as being “directly on,” “directly engaged to,” “directly connected to,” or “directly coupled to” or with another element or layer, there may be no intervening elements or layers present. Other words used to describe the relationship between elements should be interpreted in a like fashion (e.g., “between” versus “directly between,” “adjacent” versus “directly adjacent,” etc.). As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items.
[0026] Although the terms first, second, third, etc. may be used herein to describe various elements, components, regions, layers and/or sections, these elements, components, regions, layers and/or sections should not be limited by these terms. These terms may be only used to distinguish one element, component, region, layer or section from another region, layer or section. Terms such as “first,” “second,” and other numerical terms when used herein do not imply a sequence or order unless clearly indicated by the context. Thus, a first element, component, region, layer or section discussed below could be termed a second element, component, region, layer or section without departing from the teachings of the example embodiments.
[0027] Spatially relative terms, such as “inner,” “outer,” “beneath,” “below,” “lower,” “above,” “upper,” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. Spatially relative terms may be intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if the device in the figures is turned over, elements described as “below”, or “beneath” other elements or features would then be oriented “above” the other elements or features. Thus, the example term “below” can encompass both an orientation of above and below. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly.
[0028] “Substantially” is intended to mean a quantity, property, or value that is present to a great or significant extent and less than, more than or equal to total. For example, “substantially vertical” may be less than, greater than, or equal to completely vertical.
[0029] “About” is intended to mean a quantity, property, or value that is present at ±10%. Throughout this disclosure, the numerical values represent approximate measures or limits to ranges to encompass minor deviations from the given values and embodiments having about the value mentioned as well as those having exactly the value mentioned. Other than in the working examples provided at the end of the detailed description, all numerical values of parameters (e.g., of quantities or conditions) in this specification, including the appended claims, are to be understood as being modified in all instances by the term “about” whether or not “about” actually appears before the numerical value. “About” indicates that the stated numerical value allows some slight imprecision (with some approach to exactness in the value; approximately or reasonably close to the value; nearly). If the imprecision provided by “about” is not otherwise understood in the art with this ordinary meaning, then “about” as used herein indicates at least variations that may arise from ordinary methods of measuring and using such parameters. In addition, disclosure of ranges includes disclosure of all values and further divided ranges within the entire range, including endpoints given for the ranges.
[0030] Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the recited range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein.
[0031] References to “embodiment” or “variant”, e.g., “one embodiment,” “an embodiment,” “example embodiment,” “various embodiments,” etc., may indicate that the embodiment(s) or variant(s) of the invention so described may include a particular feature, structure, or characteristic, but not every embodiment necessarily includes the particular feature, structure, or characteristic. Further, repeated use of the phrase “in one embodiment,” or “in an exemplary embodiment,” do not necessarily refer to the same embodiment or variant, although they may.
[0032] As used herein the term “method” refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners in the relevant art. Unless otherwise expressed, it is in no way intended that any method or aspect set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not specifically state in the claims or descriptions that the steps are to be limited to a specific order, it is in no way intended that an order be inferred, in any respect. This holds for any possible non-express basis for interpretation, including matters of logic with respect to arrangement of steps or operational flow, plain meaning derived from grammatical organization or punctuation, or the number or type of aspects described in the specification.
[0033] As used in this application the term “layer” is intended to mean a substantially uniform material limited by interfaces between it and adjacent other layers, substrate, or environment.
[0034] This detailed description of exemplary embodiments makes reference to the accompanying drawings, which show exemplary embodiments by way of illustration. While these exemplary embodiments are described in sufficient detail to enable those skilled in the art to practice the disclosure, it should be understood that other embodiments may be realized and that logical changes and adaptations in design and construction may be made in accordance with this disclosure and the teachings herein without departing from the spirit and scope of the disclosure. Thus, the detailed description herein is presented for purposes of illustration only and not for purposes of limitation.
Biosensor Chip Preparation
[0035] In accordance with the best mode contemplated for the present invention, the PC-TIR biosensor employed in the present invention is an open optical microcavity and is based upon the PC-TIR biosensor described in U.S. Pat. No. 7,639,362 ('362 Patent), which is herein incorporated by reference in its entirety. Different from the approach taken in the '362 Patent or in previous studies (e.g., Guo, Y., Ye, J. Y., Divin, C., Thomas, T. P., Myc, A., Bersano-Begey, T. F., Baker, J. J. R. & Norris, T. B. Real-Time Biomolecular Binding Detection Using a Sensitive Photonic Crystal Biosensor. Anal. Chem. 82, 5211-5218, (2010); Zhang, B., Dallo, S., Peterson, R., Hussain, S., Weitao, T. & Ye, J. Y. Detection of anthrax lef with DNA-based photonic crystal sensors. J Biomed Opt 16, 127006, (2011); Zhang, B., Morales, A. W., Peterson, R., Tang, L. & Ye, J. Y. Label-free detection of cardiac troponin I with a photonic crystal biosensor. Biosens Bioelectron 58, 107-113, (2014); Zhang, B., Tamez-Vela, J., Solis, S., Bustamante, B., Peterson, R., Rahman, S., Morales, A., Tang, L. & Ye, J. Y. Detection of Myoglobin with open-cavity and label-free photonic crystal biosensor. Journal of Medical Engineering, 808056, (2013); Zhang, B., Wang, B., Morales, A. W., Scudder, J., Bhattacharyya, M. K. & Ye, J. Y. Study of the Interactions of Fusarium virguliforme Toxin FvTox1 with Synthetic Peptides by Molecular Simulations and a Label-Free Biosensor. Anal Chem 88, 3024-3030, (2016)), where the PC-TIR sensor was used for molecular binding assays, the present invention relies upon detecting changes in the refractive index of LAL analyte solutions caused by endotoxins. The inventive PC-TIR biosensor was designed based on numerical simulations with a transfer matrix approach and fabricated with electron-beam physical vapor deposition.
[0036] As shown in
[0037] Sample wells, analyte wells or microfluidic channels (410 in
Biosensor Apparatus
[0038] The inventive LAL assay system 400 was utilized in an angular detection mode, as shown in
Limulus Amoeboeyte Lysate (LAL) and Endotoxin Preparation
[0039] In one embodiment, an LAL reagent KTA2 (from Charles River Laboratories with a marked sensitivity of 0.005 EU/mL) was used. KTA2 is a kinetic turbidimetric reagent. The directions for proper rehydration and preparation included in the LAL reagent package were followed. The control standard endotoxin (CSE) was also purchased from Charles River Laboratories. Included in the CSE package was the Certificate of Analysis, which specifies the potency (pyrogenicity) of the dehydrated endotoxin in EU/mg. The CSE was reconstituted with LAL Reagent Water (LRW) and vortexed vigorously for 5 minutes before further dilutions. Serial dilutions were made to prepared the test solutions containing 50, 5, 0.5, 0.05, 0.005, 0.0005 EU/mL endotoxin, respectively.
Measurement Procedure
[0040] After the appropriate dilutions of CSE were made and LAL reagents were rehydrated, the baked biosensor was placed on an equilateral prism with index matching fluid as shown in
[0041] The probe laser beam focused by a cylindrical lens formed a line across three sample wells on the sensor surface simultaneously. The reflected beam of the probe laser from the sensor containing a range of different angles was projected onto an imaging chip to measure the resonant angle of the sensor. A dark line appeared on the image indicating the resonant angle determined by the refractive index of the analyte solution in the corresponding sample well. The MATLAB code and computer processed the images in real time. A background image was used to subtract the image with the dark lines, resulting in an image with three short sections of bright lines (
[0042] Sample measurements were replicated five times for each CSE concentration to make statistical analysis possible. Standard errors were calculated and plotted as error bars showing the measurement results. Standard deviations were also calculated. Because each data point consisted of the average of about 10 spectral samples, the standard error was selected as the appropriate error bar in figures showing run results. Standard deviation and the coefficient of variation were also calculated using Excel.
EXAMPLES
[0043] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds, compositions, articles, devices and/or methods claimed herein are made and evaluated, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
[0044] Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in degrees Centigrade or is at ambient temperature, and pressure is at or near atmospheric.
Results
[0045] In previous studies PC-TIR sensors were used for molecular binding assays ranging from well-studied coupling agents to small molecule binding and nucleic acid and cardiac biomarker detection (Guo et al. 2010; Guo et al. 2008; Zhang et al. 2011; Zhang et al. 2014; Zhang et al. 2013; Zhang et al. 2016, supra). In contrast, for the first time, the present invention utilizes the PC-TIR biosensor to monitor the changes in the refractive index of LAL analyte solutions, which sensitively reflects the amount of endotoxin in the test samples.
[0046] As shown in
[0047] The time dependence of the peak positions obtained from fitting the curves for six different concentrations of endotoxin ranging from 0.0005 EU/ml to 50 EU/ml as well as the control sample is shown in
[0048] To illustrate the fast response of the PC-TIR sensor to LAL assays, the derivative of the time-dependent curves of the resonant peak positions was used to determine the onset time of the coagulation process of the LAL reaction to endotoxins. The time corresponding to the minimum of each derivation curve in
[0049] When compared to a conventional turbidimetric LAL assay, i.e., from Charles River Laboratories, the inventive PC-TIR biosensor measurement demonstrated both faster assay times as well as ultrahigh sensitivity.
[0050] The data indicate that even the most diluted endotoxin solution used (0.0005 EU/mL) has resulted a curve that is clearly different from the negative control (LAL reagent mixed with water). Based on the average pyrogenicity of the endotoxin, 0.0005 EU/mL equates approximately to 0.00005 ng/mL of endotoxin in the solution, which demonstrates the superior sensitivity of this PC-TIR sensor-based approach over the conventional approaches. Compared to the best sensitivity achieved in the LAL turbidimetric test available from Charles River Laboratories, the sensitivity of the PC-TIR sensor-based approach has showed a 10-fold enhancement over the industry standard.
[0051] The inventive system and method demonstrate that an LAL assay that measures the refractive index of a test solution using a photonic crystal biosensor offers significantly enhanced sensitivity together with substantially faster discrimination of positive and negative results. In addition, the PC-TIR biosensor has a simple 1-dimensional (1D) PC structure, which is basically a multi-layered dielectric coating and can be easily fabricated with well-established vacuum deposition techniques. In contrast to 2D or 3D PC structures, the simplicity of the PC-TIR biosensor structure allows for low-cost reproduction, robust performance, and ultrahigh sensitivity assays, which are important factors for potential commercialization of this unique technique for sensitive and rapid LAL assays. The PC-TIR biosensor chips can also be reused as they are robust through a number of heat cycles.
[0052] Furthermore, there is promise in testing samples that possibly have confounding variables via extreme dilution due to the fact the LAL assays on a PC-TIR chip have a very high sensitivity. Future research is needed in this area, and a more complete list of confounding molecules can be tested with the PC-TIR chip with the endotoxin standard, blood plasma, and other analytes of interest. A method for binding the LAL proteins to the biosensor surface in conjunction with a microfluidic system may further lead to lower volumes of LAL needed to test solutions for pyrogenicity.
[0053] It is shown that the endotoxin test with a PC-TIR sensor in accordance with the described system and method offers a 10-fold enhanced sensitivity compared to commercial standard methods, along with much faster discrimination of positive and negative results. This improvement can be attributed to the unique detection principle that utilizes a new physical parameter—the refractive index of the analyte solution—to monitor the coagulation process during the reaction of the LAL reagent with the analyte solution. In addition to the sensitivity and speed, this approach also allows for using very small amounts of LAL reagents for the assays, with resultant cost savings in the quality control process for pharmaceutical and biotechnology industries, while conserving a most valuable resource; the horseshoe crab.
[0054] It has also been found that in addition to using LAL reagents, extracts from LAL reagents that include purified Factor C and/or recombinant Factor C (rFC) may be employed with the present invention. LAL testing may not include protease amplifying steps, thereby necessitating higher sensitivity biosensor be employed. The increased sensitivity of the PC-TIR biosensor in the present system and method, relative to that of conventional LAL assay systems and methods, addresses this need for higher sensitivity.
[0055] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
[0056] While the invention has been described in connection with various embodiments, it will be understood that the invention is capable of further modifications. This application is intended to cover any variations, uses or adaptations of the invention following, in general, the principles of the invention, and including such departures from the present disclosure as, within the known and customary practice within the art to which the invention pertains.